Literature DB >> 7591297

Mutated human Kirsten ras, driven by a thyroglobulin promoter, induces a growth advantage and partially dedifferentiates rat thyroid epithelial cells in vitro.

C Monaco1, D Califano, G Chiappetta, A Mineo, V De Franciscis, G Vecchio, G Santelli.   

Abstract

We have earlier shown that expression of the human activated Ki-ras, directed by the rat thyroglobulin (TG) promoter in the thyroid gland of transgenic mice, is able to induce thyroid benign tumors, albeit at low incidence. A likely explantation of our results is that the low levels of exogenous Ki-ras transcripts are not sufficient to induce multifocal tumors in the thyroid gland. We have performed experiments to analyze the effects of a similar construct in vitro upon thyroid-cell proliferation and differentiation. Transfection of FRTL-5 rat thyroid cells with the human Ki-rasval12 fused to the rat TG promoter is rapidly followed by reduced expression of the differentiation markers thyroglobulin, thyroperoxydase and thyrotropin receptor, but not by fully malignant cell transformation. The data reported support the hypothesis that Ki-ras mRNA levels are critical to the process of complete neoplastic transformation of thyroid epithelial differentiated cells in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591297     DOI: 10.1002/ijc.2910630525

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  3 in total

1.  Thyroid cancer: pathogenesis and targeted therapy.

Authors:  David A Liebner; Manisha H Shah
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 2.  Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

3.  Oncogenic ras blocks the cAMP pathway and dedifferentiates thyroid cells via an impairment of pax8 transcriptional activity.

Authors:  Maria Giuseppina Baratta; Immacolata Porreca; Roberto Di Lauro
Journal:  Mol Endocrinol       Date:  2009-03-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.